Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage

Patent metadata

Field	Value
Publication number	US-10668059-B2
Application number	US-201715648119-A
Country	US
Kind code	B2
Filing date	Jul 12, 2017
Priority date	Mar 27, 2012
Publication date	Jun 2, 2020
Grant date	Jun 2, 2020

Abstract

Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.

First claim

What is claimed is:

1. A method of inhibiting vascular leakage in a subject having a Japanese encephalitis virus (JEV) infection, the method comprising:
(a) obtaining a biological sample from the subject;
(b) determining the level of chymase, tryptase, or a combination thereof in the biological sample from the subject;
(c) comparing the level of chymase, tryptase, or a combination thereof in the biological sample to a reference level of chymase, tryptase, or a combination thereof;
(d) identifying the subject as having a JEV infection if the level of chymase, tryptase, or a combination thereof is greater than the reference level of chymase, tryptase, or a combination thereof; and
(e) administering a mast cell modulator to the subject identified as having a JEV infection, wherein the mast cell modulator comprises cromolym, ketotifen, or montelukast.

2. The method of claim 1 , wherein the reference level of chymase, tryptase, or a combination thereof is the level of chymase, tryptase, or a combination thereof in a control sample from a healthy patient.

3. The method of claim 2 , wherein the reference level is about 0.18 ng/mL to about 0.5 ng/mL.

4. The method of claim 1 , wherein the reference level 9f chymase, tryptase, or a combination thereof is the level of chymase, tryptase, or a combination thereof in a control sample from a patient having a mild form of JEV infection.

5. The method of claim 1 , wherein the reference level is about 0.8 ng/mL to about 6.0 ng/mL.

6. The method of claim 1 , wherein the reference level of chymase, tryptase, or a combination thereof is the level of chymase, tryptase, or a combination thereof in a control sample from a patient having a severe form of JEV infection.

7. The method of claim 6 , wherein the reference level is greater than about 6.0 ng/mL.

8. The method of claim 2 , wherein the level of chymase, tryptase, or a combination thereof in the biological sample is at least two times greater than the level of chymase, tryptase, or a combination thereof in the control sample.

9. A method of inhibiting vascular leakage in a subject having a mild or severe form of Japanese encephalitis virus (JEV) infection, the method comprising:
(a) obtaining a biological sample from the subject;
(b) determining the level of chymase, tryptase, or a combination thereof in the biological sample from the subject;
(c) comparing the level of chymase, tryptase, or a combination thereof in the biological sample to a first reference level of chymase, tryptase, or a combination thereof and a second reference level of chymase, tryptase, or a combination thereof;
(d) correlating the level of chymase, tryptase, or a combination thereof in the biological sample with the mild or severe form of JEV infection in the subject, wherein if the level of chymase, tryptase, or a combination thereof is greater than the first reference level and the second reference level, the subject is diagnosed as having the severe form of JEV infection, and wherein if the level of chymase, tryptase, or a combination thereof is greater than the first reference level but less than the second reference level, the subject is diagnosed as having the mild form of JEV infection; and
(e) administering a mast cell modulator with an aggressive treatment regimen to the subject identified as having the severe form of JEV infection or administering a mast cell modulator to the subject identified as having the mild form of JEV infection, wherein the mast cell modulator comprises cromolym, ketotifen, or montelukast.

10. The method of claim 9 , wherein the first reference level is the level of chymase, tryptase, or a combination thereof in a first control sample and the second reference level is the level of chymase, tryptase, or a combination thereof in a second control sample.

11. The method of claim 1 , wherein the biological sample of a subject is selected from the group consisting of tissue sample, bodily fluid, whole blood, plasma, serum, urine, bronchoalveolar lavage fluid, saliva, tissue biopsy, and a cell culture suspension or fraction thereof.

12. The method of claim 1 , wherein the mast cell modulator comprises montelukast.

13. The method of claim 9 , wherein the aggressive treatment regimen comprises transfusing fresh blood or platelets, administering intravenous fluids, administering intravenous fluids and electrolytes, or administering oxygen therapy.

Assignees

• Univ Duke

Inventors

• Abraham Soman N
• St John Ashley L

Classifications

• Y02A50/393

  Cross-Sectional Technologies · mapped topic

• A61K38/55

  Protease inhibitors · CPC title

• G01N2333/175

  Bunyaviridae, e.g. California encephalitis virus, Rift valley fever virus, Hantaan virus · CPC title

• Y02A50/389

  Cross-Sectional Technologies · mapped topic

• A61K31/55

  having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title